Gray Natalie N, Villalobos Lindsay R, Matherne Milre, Schadler Aric, Bosley Tyler E
Department of Pharmacy (NNG, LRV, TEB), University of Kentucky Healthcare, Lexington, KY.
College of Pharmacy (MM, AS, TEB), University of Kentucky Lexington, KY.
J Pediatr Pharmacol Ther. 2022;27(7):649-654. doi: 10.5863/1551-6776-27.7.649. Epub 2022 Sep 26.
Pediatric oncology patients endure treatments that may include chemotherapy, surgery, radiation, and transplant. These treatment modalities often have an effect on a patient's mental health. To date, little is known or published about the association between certain cancer treatment regimens and the use of psychotropic medications. The goal of this study is to identify associations between the use of psychotropic medications in pediatric oncology patients in relation to the intensity of their oncologic treatment regimen.
A retrospective chart review was completed for pediatric oncology patients seen between the years of 2009 and 2019 with prescriptions and/or inpatient orders for specific psychotropic medications. The intensity of the oncologic regimen was categorized using the Intensity of Treatment Rating Scale (ITR-3) tool. Association between the intensity of therapy and use of psychotropic medications were compared using Pearson χ and Fisher exact tests as appropriate.
There were 172 patients identified as having inpatient and/or outpatient orders for psychotropic medications during the study period. Ninety-one pediatric oncology patients were included in data analysis. It was found that psychotropic medications were used consistently in pediatric oncology patients despite a specific ITR-3 score. There were no statistically significant associations found when comparing ITR-3 scores to psychotropic medication use or to age at diagnosis.
Significance was not obtained in this study; however, we found that psychotropic medications were used across the spectrum of diagnoses, age, and oncologic treatment intensity. This suggests that all pediatric oncology patients should be evaluated for psychiatric needs throughout their course of oncologic treatment.
儿科肿瘤患者要接受包括化疗、手术、放疗和移植在内的治疗。这些治疗方式常常会对患者的心理健康产生影响。迄今为止,关于某些癌症治疗方案与精神类药物使用之间的关联,人们了解甚少且鲜有相关报道。本研究的目的是确定儿科肿瘤患者使用精神类药物与肿瘤治疗方案强度之间的关联。
对2009年至2019年间就诊的儿科肿瘤患者进行回顾性病历审查,这些患者有特定精神类药物的处方和/或住院医嘱。使用治疗强度评定量表(ITR-3)工具对肿瘤治疗方案的强度进行分类。根据情况,使用Pearson χ检验和Fisher精确检验比较治疗强度与精神类药物使用之间的关联。
在研究期间,有172名患者被确定有精神类药物的住院和/或门诊医嘱。91名儿科肿瘤患者纳入数据分析。结果发现,尽管ITR-3评分不同,但儿科肿瘤患者持续使用精神类药物。将ITR-3评分与精神类药物使用情况或诊断时的年龄进行比较时,未发现有统计学意义的关联。
本研究未得出显著结果;然而,我们发现精神类药物在各种诊断、年龄和肿瘤治疗强度的患者中都有使用。这表明所有儿科肿瘤患者在整个肿瘤治疗过程中都应接受精神科需求评估。